CTLA4 and neoplasm: For samples from MSS CRC patients treated with anti-PD-1 + anti-CTLA4 ICBs together with radiotherapy (NCT03104439)103, the only partially responding CRC patient (PR) with tumor transcriptomic data had higher ISC2 score than ISC3, whereas in non-responders (SD + PD) there was no clear trend (Supplementary Fig. S8d).